Although Novartis' Cosentyx showed numerically higher results for its primary endpoint, it failed...
CVB, Parexel Biotech partner on adaptive platform trial of PTSD
Nonprofit research organisation Cohen Veterans Bioscience (CVB) has formed a strategic partnership with Parexel’s new division Parexel Biotech.
Novartis’ Cosentyx sees mixed results from head-to-head with Humira
Although Novartis' Cosentyx showed numerically higher results for its primary endpoint, it failed to demonstrate statistically significant superiority over AbbVie's Humira.
AstraZeneca’s anifrolumab shows promise in trial for SLE
AstraZeneca has reported that anifrolumab reduced disease activity in the Phase III TULIP 2 study involving patients with moderate to severe systemic lupus erythematosus (SLE).
Janssen’s Tremfya meets primary endpoint in Discover studies
Janssen Pharmaceutical has reported positive data from the Phase III Discover-1 and Discover-2 clinical trials of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA).
Roche and PTC report positive data for risdiplam in SMA
Roche and PTC Therapeutics have reported positive results from the second part of the SUNFISH trial of risdiplam to treat spinal muscular atrophy (SMA).
FDA faces conundrum over future of AMAG’s Makena following drug withdrawal
GlobalData believes that either an FDA decision to remove the drug from the market or a request for a new confirmatory trial will have significant implications for patients and the company.
Genentech’s Gazyva improves renal response in lupus nephritis patients
Roche subsidiary Genentech has reported improved complete renal response (CRR) in proliferative lupus nephritis patients treated with Gazyva (obinutuzumab) in a Phase II NOBILITY clinical trial.
Daiichi Sankyo’s Phase III trial of esaxerenone meets primary goal
Daiichi Sankyo has reported positive data from the Phase III clinical trial of esaxerenone to treat patients with incipient diabetic nephropathy, which is type 2 diabetes with microalbuminuria, in Japan.
EIP Pharma reports mixed results from neflamapimod Alzheimer’s trial
EIP Pharma has reported data from the Phase IIb REVERSE-SD clinical trial of brain-penetrant drug neflamapimod in patients suffering from early-stage Alzheimer’s disease.
ObsEva plans to halt clinical programme of IVF nolasiban drug
Biopharmaceutical firm ObsEva will end the current clinical development programme of nolasiban IVF after the drug failed in the Phase III IMPLANT 4 clinical trial in Europe.